William Blair Issues Pessimistic Outlook for ARCT Earnings

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) – William Blair cut their Q1 2025 earnings per share (EPS) estimates for Arcturus Therapeutics in a report issued on Thursday, March 13th. William Blair analyst M. Minter now forecasts that the biotechnology company will post earnings of ($1.39) per share for the quarter, down from their prior estimate of ($0.53). The consensus estimate for Arcturus Therapeutics’ current full-year earnings is ($2.22) per share. William Blair also issued estimates for Arcturus Therapeutics’ Q2 2025 earnings at ($1.41) EPS, Q3 2025 earnings at ($1.15) EPS, Q4 2025 earnings at ($1.36) EPS, FY2025 earnings at ($5.31) EPS, Q1 2026 earnings at ($1.39) EPS, Q2 2026 earnings at ($1.48) EPS, Q3 2026 earnings at ($1.52) EPS, Q4 2026 earnings at ($1.59) EPS, FY2026 earnings at ($5.98) EPS and FY2027 earnings at $0.41 EPS.

Arcturus Therapeutics (NASDAQ:ARCT) last released its earnings results on Thursday, March 6th. The biotechnology company reported ($1.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.78). Arcturus Therapeutics had a negative return on equity of 22.39% and a negative net margin of 36.39%. The firm had revenue of $22.77 million for the quarter, compared to analyst estimates of $44.64 million.

ARCT has been the topic of a number of other reports. BTIG Research set a $48.00 target price on Arcturus Therapeutics and gave the stock a “buy” rating in a research report on Monday, March 10th. Wells Fargo & Company decreased their price objective on Arcturus Therapeutics from $58.00 to $50.00 and set an “overweight” rating on the stock in a report on Friday, March 7th. HC Wainwright decreased their price objective on Arcturus Therapeutics from $63.00 to $60.00 and set a “buy” rating on the stock in a report on Friday, March 7th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Arcturus Therapeutics in a report on Friday, March 7th. Finally, Canaccord Genuity Group decreased their price objective on Arcturus Therapeutics from $74.00 to $68.00 and set a “buy” rating on the stock in a report on Monday, March 10th. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $59.20.

Arcturus Therapeutics Stock Up 1.3 %

ARCT stock opened at $14.08 on Monday. Arcturus Therapeutics has a twelve month low of $12.75 and a twelve month high of $45.00. The company has a market cap of $381.85 million, a PE ratio of -6.34 and a beta of 2.96. The business’s 50-day simple moving average is $16.64 and its 200 day simple moving average is $18.29.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the company. Wellington Management Group LLP raised its stake in shares of Arcturus Therapeutics by 0.8% in the fourth quarter. Wellington Management Group LLP now owns 97,036 shares of the biotechnology company’s stock valued at $1,647,000 after acquiring an additional 742 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Arcturus Therapeutics by 10.8% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,694 shares of the biotechnology company’s stock valued at $202,000 after acquiring an additional 846 shares during the last quarter. Ameriprise Financial Inc. raised its stake in shares of Arcturus Therapeutics by 5.0% in the fourth quarter. Ameriprise Financial Inc. now owns 18,613 shares of the biotechnology company’s stock valued at $316,000 after acquiring an additional 883 shares during the last quarter. Virtus ETF Advisers LLC raised its stake in shares of Arcturus Therapeutics by 38.8% in the fourth quarter. Virtus ETF Advisers LLC now owns 4,051 shares of the biotechnology company’s stock valued at $69,000 after acquiring an additional 1,132 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD raised its stake in shares of Arcturus Therapeutics by 7.2% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 19,018 shares of the biotechnology company’s stock valued at $323,000 after acquiring an additional 1,279 shares during the last quarter. Institutional investors own 94.54% of the company’s stock.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.